Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (C.sub.max) of at least 750 pg/ml, (b) with a mean time to C.sub.max (T.sub.max) of DHE of less than 45 minutes, and (c) a mean plasma AUC.sub.0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

Described herein are an interactive apparatus and methods for sensing and measuring real-time characteristic patterns of a subject's use of a dry powder inhalation system. The inhaler device can be used in a wireless communication mode to communicate with a display to assess the subject's usage of the inhalation system concurrently as the inhalation is performed and thus the subject's inhalation can be evaluated as well as the performance of the inhalation system. The system can also detect the identity of the medicament, its dosage, lot, expiration, etc. and the characteristic profile of a dry powder formulation emitted from the inhalation system in use and allows effective delivery of powder doses. Data obtained can be transmitted to a digital application and can be analyzed for optimal therapeutic utility.

An inhaler for powdered medicaments is provided. It consists of a substantially smoking pipe-shaped hollow body that has a first portion, for housing a cartridge of powdered medicament, and a second portion for delivering the medicament by means of an airstream that carries the powder from an inner drop region along a delivery duct whose end is suitable to be placed in a patient's mouth, the intake of the air being achieved through at least three air intakes arranged symmetrically with respect to the longitudinal midplane of the inhaler, which includes a support base for the cartridge in which oriented flow channels are formed that extend between the three air intakes and the inner powder drop region.

Methods and devices for delivering a dose, such as a medicament, for inhalation. A dose may be stored by a delivery device and dispersed and delivered in a metered fashion to a subject, such as by the subject inhaling via a mouthpiece of the delivery device. One or more chambers of the device may have a toroidal shape and may be arranged to be selectively opened for fluid communication with a flow path of the delivery device, such as by sliding the chamber relative to a portion of the flow path. The flow path may include a restriction that permits air to bypass the chamber, and/or the chamber may be arranged so that fluid entering the chamber interacts with fluid exiting the chamber so as to enhance dispersion of the dose.

A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided.

A cartridge for an aerosol-generating system may include a first chamber housing defining a first chamber and a second chamber housing defining a second chamber that is separate from the first chamber. The first chamber may contain an aerosol-forming substrate in the form of a gel, and the second chamber may contain a source of a desired compound. The first and second chamber housings may be separate or separable structures.

Various exemplary drug syringes with a mechanical stop for a second dose, drug products utilizing the same, and methods of using drug syringes with a mechanical stop for a second dose are provided. In general, a nasal drug delivery device is configured to dispense therefrom first and second doses of a drug therefrom into a nose. The drug delivery device includes a mechanical stop configured to provide a pause between the delivery of the first and second doses. During the pause, a user of the drug delivery device can move the drug delivery device from one nostril, into which the first dose was sprayed, to another nostril, into which the second dose can be sprayed. The mechanical stop is configured to hold the drug delivery device in a static delivery state.

Various exemplary drug holders (102, 200) for drug delivery devices (100), drug products utilizing the same, and methods of using drug holders for drug delivery devices are provided. In general, a nasal drug delivery device is configured to dispense therefrom at least one dose of a drug therefrom into a nose. The drug delivery device includes a drug holder that contains the drug therein that is delivered out of the drug delivery device. The drug holder can include two cavities (208, 210) therein that are fluidically sealed from one another prior to use of the drug delivery device to cause drug delivery. A first one of the cavities includes the drug therein, and a second one of the cavities includes a drug or air therein.

Various exemplary drug delivery devices with multiple drug vials, drug products utilizing the same, and methods of using drug delivery devices with multiple drug vials are provided. In general, a nasal drug delivery device configured to dispense a drug therefrom into a nose and includes two or more vials each containing the drug therein. The drug delivery device is configured to deliver the drug from each of the vials for a total of two or more sprays into the nose. The same drug delivery device may therefore deliver multiple drug sprays to a user. In some embodiments, instead of including two or more vials that collectively contain enough drug therein for more than two drug sprays, the drug delivery device can include a single vial that contains enough drug therein for more than two drug sprays.